Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2025-02-05 DOI:10.1093/cid/ciae256

Phyo Pyae Nyein, Kathy Petoumenos, Margaret Borok, Nnakelu Eriobu, Nagalingeswaran Kumarasamy, Anchalee Avihingsanon, Iskandar Azwa, Sounkalo Dao, Mohamed Cisse, Nila J Dharan, Josh Hanson, Gail V Matthews

引用次数: 0

Abstract

In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain.

查看原文本刊更多论文

抗逆转录病毒疗法与血压变化之间的关系：D2EFT 研究的结果。

在这项在 14 个中低收入国家进行的随机对照研究中，与服用两种核苷类逆转录酶和达鲁那韦/利托那韦的患者相比，服用多罗替拉韦和达鲁那韦/利托那韦 48 周的患者收缩压和舒张压的升高幅度更大。在控制了包括体重增加在内的混杂因素后，这一差异仍然显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.